Re:Site Visit-18-03-15, page-152

Despite the positive tone in many of the Philips presentations, it's clear that Philips have had some issues with the troponin test. This was mentioned, briefly when bioMérieux decided to exit the collaboration. It's only natural for Philips to put on a brave face, they have invested a huge amount on cash into this project.

bioMérieux - First-Quarter 2014 Business Review - April 2014

"Partnership with Philips in automated Point-of-Care (POC)
At the end of March, given the challenges that bioMérieux sees in developing troponin solutions delivering comparable performance to central laboratory analyzers, the Company decided not to pursue its collaboration with Philips aimed at developing a fully automated handheld diagnostic testing solutions for hospital use that can be deployed at the point-of-care - i.e. close to the patient."

To paraphrase. "We can't make it work to clinical standards, so we're out of here"

Interesting timing of the announcement too.